Market Cap
€103.4m
Last Updated
2020/06/05 21:38 UTC
Data Sources
Company Financials +
Executive Summary
Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -20.2% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has Oxurion's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OXUR has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
4.2%
OXUR
7.3%
BE Biotechs
10.1%
BE Market
1 Year Return
-25.4%
OXUR
80.1%
BE Biotechs
-13.2%
BE Market
Return vs Industry: OXUR underperformed the Belgian Biotechs industry which returned 79.1% over the past year.
Return vs Market: OXUR underperformed the Belgian Market which returned -16.7% over the past year.
Shareholder returns
| OXUR | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.2% | 7.3% | 10.1% |
| 30 Day | -3.9% | 48.3% | 13.9% |
| 90 Day | -5.6% | 49.8% | 1.2% |
| 1 Year | -25.4%-25.4% | 80.1%80.1% | -12.1%-13.2% |
| 3 Year | -15.3%-15.3% | 379.2%379.2% | -22.1%-26.6% |
| 5 Year | -48.4%-48.4% | 331.0%331.0% | -17.6%-26.3% |
Price Volatility Vs. Market
How volatile is Oxurion's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Do Insiders Own Shares In Oxurion NV (EBR:OXUR)?4 weeks ago | Simply Wall St
Is Oxurion (EBR:OXUR) In A Good Position To Deliver On Growth Plans?1 month ago | Simply Wall St
The Oxurion (EBR:OXUR) Share Price Is Down 59% So Some Shareholders Are Wishing They SoldValuation
Is Oxurion undervalued compared to its fair value and its price relative to the market?
1.94x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OXUR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OXUR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OXUR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: OXUR is unprofitable, so we can't compare its PE Ratio to the Belgian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OXUR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OXUR is good value based on its PB Ratio (2x) compared to the BE Biotechs industry average (3.3x).
Next Steps
Future Growth
How is Oxurion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-20.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OXUR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OXUR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OXUR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OXUR's revenue (75.6% per year) is forecast to grow faster than the Belgian market (2.8% per year).
High Growth Revenue: OXUR's revenue (75.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OXUR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Oxurion performed over the past 5 years?
7.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OXUR is currently unprofitable.
Growing Profit Margin: OXUR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OXUR is unprofitable, but has reduced losses over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare OXUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OXUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: OXUR has a negative Return on Equity (-97.74%), as it is currently unprofitable.
Next Steps
Financial Health
How is Oxurion's financial position?
Financial Position Analysis
Short Term Liabilities: OXUR's short term assets (€57.0M) exceed its short term liabilities (€10.4M).
Long Term Liabilities: OXUR's short term assets (€57.0M) exceed its long term liabilities (€1.3M).
Debt to Equity History and Analysis
Debt Level: OXUR is debt free.
Reducing Debt: OXUR has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OXUR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OXUR has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 9.9% each year.
Next Steps
Dividend
What is Oxurion's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OXUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OXUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OXUR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OXUR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OXUR's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Patrik De Haes
11.75yrs
Tenure
€557,000
Compensation
Dr. Patrik De Haes, ViBio, BVBA, MD, has been the Chief Executive Officer of ThromboGenics NV since September 1, 2008. Dr. De Haes serves as an Executive Director of ThromboGenics NV. Dr. Haes serves as Ex ...
CEO Compensation Analysis
Compensation vs Market: Patrik's total compensation ($USD630.95K) is above average for companies of similar size in the Belgian market ($USD446.72K).
Compensation vs Earnings: Patrik's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Acting CMO & Executive Director | 11.75yrs | €557.00k | no data | |
| Chief Financial Officer | 5.42yrs | no data | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Global Head of Corporate Communications & Investor Relations | no data | no data | no data | |
| Head of HR | no data | no data | no data | |
| Global Head of Development | no data | no data | no data | |
| Head of Product Supply | no data | no data | no data | |
| Global Head of Drug Safety & Medical Affairs | 3.83yrs | no data | no data | |
| Chief Commercial Officer | 2.58yrs | no data | no data |
4.6yrs
Average Tenure
Experienced Management: OXUR's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Acting CMO & Executive Director | 11.75yrs | €557.00k | no data | |
| Non-Executive Independent Director | 1.67yrs | €34.00k | no data | |
| Non-Executive Independent Director | 4.92yrs | €36.00k | 6.07% €6.3m | |
| Non-Executive Director | 6.5yrs | €69.00k | no data | |
| Independent Chairman | 3yrs | €60.00k | 8.78% €9.1m | |
| Non-Executive Independent Director | 5.08yrs | €42.00k | no data |
4.9yrs
Average Tenure
61.5yo
Average Age
Experienced Board: OXUR's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Oxurion NV's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Oxurion NV
- Ticker: OXUR
- Exchange: ENXTBR
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €103.388m
- Shares outstanding: 38.29m
- Website: https://www.oxurion.com
Number of Employees
Location
- Oxurion NV
- Gaston Geenslaan 1
- Leuven
- Flemish Brabant
- 3001
- Belgium
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OXUR | ENXTBR (Euronext Brussels) | Yes | Ordinary Bearer Shares | BE | EUR | Jul 2006 |
| 0G99 | LSE (London Stock Exchange) | Yes | Ordinary Bearer Shares | GB | EUR | Jul 2006 |
| TBGN.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Bearer Shares | US | USD | Jul 2006 |
| TG4 | DB (Deutsche Boerse AG) | Yes | Ordinary Bearer Shares | DE | EUR | Jul 2006 |
Biography
Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally. Its lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of DME that has completed phase 1 clinical trial; THR-687 an integrin antagonist to treat patients with a diabetic eye disease that has completed phase 1 clinical trial; and TB-403, an anti- placental growth factor for the treatment of medulloblastoma, a pediatric malignant brain tumor. It has collaboration agreements with BioInvent International AB, Bicycle Therapeutics, Parexel, INC Research, and Galapagos. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/05 21:38 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.